Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Medicare For All' Bills Prompt Warning From Former US FDA Commissioner Gottlieb

Executive Summary

In an address to the National Press Club on 10 May, former FDA Commissioner Scott Gottlieb pointed to some of the challenges that CMS would face in supplying coverage for new technology, should a "Medicare for All" bill be adopted by Congress and signed by the president. Medtech Insight analyzed provisions that could impact industry in some of the proposed bills, in a comparative chart.

You may also be interested in...



Billions Of Dollars Of US Device Sales At Stake From Medicare For All Bills, GOP Members Say

A Republican congressman at a recent House hearing said that billions of dollars of medical device sales would be legislated out of existence by Medicare for All Act legislation, while Democrats argued that health care costs borne by US employers and employees already gobble up 18% of US gross domestic product, and adoption of a single-payer would lower these costs.

From Regulation To Reimbursement: Ex-FDA Chief Says CMS Needs New Reimbursement Frameworks

Following his recent talk at the National Press Club on reimbursement issues, former US FDA Commissioner Scott Gottlieb told Medtech Insight a new breakthrough device rule proposed by the Medicare agency CMS is good but will still be economically unfeasible for many hospitals. Instead, he says new frameworks need to be developed for the new kinds of technologies coming to market.

Medtech CEOs Like Stryker's Lobo 'Scared' Of 'Medicare For All' Driving Lower Device Prices, Former CMS Chief Says

Former CMS Administrator Thomas Scully says device companies like Stryker Corp. are "scared to death" of the coming "Medicare for All" debate in Congress. But Stryker CEO Kevin Lobo disagrees, noting he can sell hip and knee replacements in single-payer countries as easily as in the US. Industry group AdvaMed – of which Lobo is the current chairman of the board – is taking a wait-and-see attitude before jumping into the debate, says chief advocacy officer Greg Crist.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT125096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel